← Back to Comera Life Sciences Holdings Stock
Comera Life Sciences Holdings (CMRA) News
WOBURN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (OTCQB: CMRA) (“Comera” or the “Company”), a life sciences company developing a proprietary drug-delivery technology to improve patient access, safety, and convenience, today announced the closing of a bridge financing with a syndicate of investors. Following the closing, the investors exercised a purchase option to acquire all of the outstanding common stock of the Company not already held by the investors to take the Company private. The financing and option exercise follows a robust effort by the Company, led by a Special Committee of the Company's Board of Directors, to explore strategic alternatives to maximize shareholder value.
Comera Life Sciences explores strategic alternatives including acquisitions, sales, mergers, and financing, with possible outcomes of reorganization or…
WOBURN, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (OTCQB: CMRA) (“Comera” or the “Company”), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced that it has initiated a process to explore strategic alternatives to maximize shareholder value.
Dorothy Clarke , Board Member at Comera Life Sciences (NASDAQ: CMRA ), reported a large acquisition of company stock options on November 13, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Monday showed that Clarke, Board Member at Comera Life Sciences, a company in the Health Care sector, was just awarded stock options worth 14,200 shares of CMRA. The options give Clarke the right to buy the company''s stock at $0.35 per share. Comera Life Sciences shares are trading up 13.35% at $0.28 at the time of this writing on Monday morning. Since the current price is $0.28, this makes Clarke''s 14,200 shares worth $4,025. Now … Full story available on Benzinga.com
WOBURN, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced it appointed Dorothy Clarke to its board of directors.
Comera Life Sciences press release (NASDAQ:CMRA): Q3 GAAP EPS of -$0.10.Revenue of $0.14M (-41.7% Y/Y).Comera had approximately $1.8 million in cash at…
– Final stage of technical evaluation near completion in Comera's research collaboration with Regeneron, a leading U.S. biotechnology company –
WOBURN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today will present research demonstrating Comera’s SQore platform capabilities in the development of subcutaneous monoclonal antibody formulations at the PODD: Partnerships
WOBURN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today will present research demonstrating Comera's SQore™ platform capabilities in the development of subcutaneous monoclonal antibody formulations at the PODD: Partnerships in Drug Delivery conference in Boston, Mass.
David Soane , 10% Owner at Comera Life Sciences (NASDAQ: CMRA ), reported a large insider buy on September 12, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Tuesday showed that Soane purchased 117,360 shares of Comera Life Sciences. The total transaction amounted to $59,994. Comera Life Sciences shares are trading up 2.69% at $0.39 at the time of this writing on Wednesday morning. Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm. Why Insider Transactions Are Important Insider transactions shouldn''t be used … Full story available on Benzinga.com